StockData
ANIPNasdaqPharmaceutical PreparationsFiscal year ends December 31

ANI PHARMACEUTICALS INC

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026
$72.56+0.27 (+0.37%)

Close on Oct 19, 2026

Market cap
$1.59B
P/E (TTM)
15.4
Dividend yield
–

Earnings

Next report expected Nov 6, 2026, before market open (estimated from past report dates)

QuarterReportedTimeRevenueEPS (GAAP)EPS (adjusted)
Q2 FY2026
Ended Jun 30, 2026
Aug 7, 2026Before market open$266.00M$1.05$2.21
Q1 FY2026
Ended Mar 31, 2026
May 8, 2026Before market open$237.50M$1.28$2.05
Q4 FY2025
Ended Dec 31, 2025
Feb 27, 2026Before market open$247.10M$1.18$2.33
Q3 FY2025
Ended Sep 30, 2025
Nov 7, 2025Before market open$227.80M$1.13$2.04
Q2 FY2025
Ended Jun 30, 2025
Aug 8, 2025Before market open$211.40M$0.36$1.80
Q1 FY2025
Ended Mar 31, 2025
May 9, 2025Before market open$197.10M$0.69$1.70
Q4 FY2024
Ended Dec 31, 2024
Jan 13, 2025Before market open–––
Q3 FY2024
Ended Sep 30, 2024
Nov 8, 2024Before market open$148.30M$-1.27$1.34
Q2 FY2024
Ended Jun 30, 2024
Aug 6, 2024Before market open–––
Q1 FY2024
Ended Mar 31, 2024
May 10, 2024Before market open–––
Q4 FY2023
Ended Dec 31, 2023
Feb 29, 2024Before market open–––

Company guidance

Outlook given with results on Aug 7, 2026, compared with the previous outlook

MeasurePeriodGuidancevs. prior
Adjusted Non-GAAP EBITDA Growthnon-GAAPFull Year 202624% to 31% growthNew
adjusted non-GAAP EBITDAnon-GAAPfull year 2026$285.00M to $300.00MMaintained
Adjusted Non-GAAP Diluted EPS Growthnon-GAAPFull Year 202616% to 23% growthNew
Adjusted Non-GAAP Diluted EPSnon-GAAPFull Year 2026$9.19 to $9.69Maintained
adjusted non-GAAP gross marginnon-GAAPfull year59.9% to 60.9%Maintained
shares outstanding for the purpose of calculating full year adjusted non-GAAP diluted EPSnon-GAAPfull year21.5 to 21.8Maintained
annual U.S. GAAP effective tax rateGAAPannual26% to 28%Maintained
Net Revenue (Total Company) GrowthFull Year 202622% to 29% growthNew
Cortrophin Gel net revenue growthfull year50% to 55% growthRaised
ILUVIEN Net Revenue GrowthFull Year 20264% to 11% growthLowered
total net revenuefull year 2026$1.08B to $1.14BMaintained
Cortrophin Gel net revenuefull year$520.00M to $540.00MLowered
ILUVIEN Net RevenueFull Year 2026$78.00M to $83.00MLowered

Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.

Press releases

Announcements Ani Pharmaceuticals filed with the SEC